

Bacteriophage targeting of gut bacterium attenuates alo

Nature

575, 505-511

DOI: [10.1038/s41586-019-1742-x](https://doi.org/10.1038/s41586-019-1742-x)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Microbial clues to a liver disease. <i>Nature</i> , 2019, 575, 451-453.	13.7	5
2	Gut viruses firm the "Great Wall". <i>Precision Clinical Medicine</i> , 2019, 2, 209-212.	1.3	0
3	Virtual and augmented reality enhanced by touch. <i>Nature</i> , 2019, 575, 453-454.	13.7	8
4	Gut microbiota in non-alcoholic fatty liver disease and alcohol-related liver disease: Current concepts and perspectives. <i>Hepatology Research</i> , 2020, 50, 407-418.	1.8	35
5	Manipulating the gut microbiota to combat alcoholic hepatitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 3-3.	8.2	7
6	Hope for alcoholics from phage therapy?. <i>Environmental Microbiology</i> , 2020, 22, 537-539.	1.8	1
7	Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. <i>Gut</i> , 2020, 69, 764-780.	6.1	112
8	Potential applications of microfluidics based blood brain barrier (BBB)-on-chips for in vitro drug development. <i>Biomedicine and Pharmacotherapy</i> , 2020, 132, 110822.	2.5	31
9	Potential Applications of Human Viral Metagenomics and Reference Materials: Considerations for Current and Future Viruses. <i>Applied and Environmental Microbiology</i> , 2020, 86, .	1.4	13
10	Changes in the fecal bacterial microbiota associated with disease severity in alcoholic hepatitis patients. <i>Gut Microbes</i> , 2020, 12, 1785251.	4.3	60
11	Transcriptomic Profiling Identifies Novel Hepatic and Intestinal Genes Following Chronic Plus Binge Ethanol Feeding in Mice. <i>Digestive Diseases and Sciences</i> , 2020, 65, 3592-3604.	1.1	11
12	Microbiota reprogramming for treatment of alcohol-related liver disease. <i>Translational Research</i> , 2020, 226, 26-38.	2.2	4
13	Intestinal permeability and bacterial translocation in patients with liver disease, focusing on alcoholic aetiology: methods of assessment and therapeutic intervention. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482094261.	1.4	18
14	Neutrophils interact with cholangiocytes to cause cholestatic changes in alcoholic hepatitis. <i>Gut</i> , 2021, 70, gutjnl-2020-322540.	6.1	19
15	Gut Microbiota and Liver Interaction through Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. <i>Journal of Clinical Medicine</i> , 2020, 9, 2488.	1.0	28
16	Engineered Live Biotherapeutics: Progress and Challenges. <i>Biotechnology Journal</i> , 2020, 15, e2000155.	1.8	13
17	Functional Microbiomics Reveals Alterations of the Gut Microbiome and Host Co-Metabolism in Patients With Alcoholic Hepatitis. <i>Hepatology Communications</i> , 2020, 4, 1168-1182.	2.0	22
18	Microbiota on biotics: probiotics, prebiotics, and synbiotics to optimize growth and metabolism. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 319, G382-G390.	1.6	26

#	ARTICLE	IF	CITATIONS
19	How Food Affects Colonization Resistance Against Enteropathogenic Bacteria. <i>Annual Review of Microbiology</i> , 2020, 74, 787-813.	2.9	27
20	Alcoholic hepatitis: Towards an era of personalised management. <i>United European Gastroenterology Journal</i> , 2020, 8, 995-1002.	1.6	3
21	Microbiota and Fatty Liver Disease—The Known, the Unknown, and the Future. <i>Cell Host and Microbe</i> , 2020, 28, 233-244.	5.1	115
22	Characterizing Phage-Host Interactions in a Simplified Human Intestinal Barrier Model. <i>Microorganisms</i> , 2020, 8, 1374.	1.6	12
23	Shining Light on Human Gut Bacteriophages. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 481.	1.8	47
24	Characterization of the Bacteriophage vB_EfaS-271 Infecting <i>Enterococcus faecalis</i> . <i>International Journal of Molecular Sciences</i> , 2020, 21, 6345.	1.8	13
25	The Gut Barrier, Intestinal Microbiota, and Liver Disease: Molecular Mechanisms and Strategies to Manage. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8351.	1.8	67
26	Functional Microbial Responses to Alcohol Abstinence in Patients With Alcohol Use Disorder. <i>Frontiers in Physiology</i> , 2020, 11, 370.	1.3	11
27	A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. <i>Journal of Clinical Medicine</i> , 2020, 9, 1369.	1.0	22
28	Manipulation of Alcohol and Short-Chain Fatty Acids in the Metabolome of Commensal and Virulent <i>Klebsiella pneumoniae</i> by Linolenic Acid. <i>Microorganisms</i> , 2020, 8, 773.	1.6	5
29	Recent advances of sterile inflammation and inter-organ cross-talk in alcoholic liver disease. <i>Experimental and Molecular Medicine</i> , 2020, 52, 772-780.	3.2	34
30	Contribution of the Intestinal Microbiome and Gut Barrier to Hepatic Disorders. <i>Gastroenterology</i> , 2020, 159, 849-863.	0.6	202
31	Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?. <i>Physiology</i> , 2020, 35, 261-274.	1.6	28
32	Bacteriophage-mediated manipulation of the gut microbiome — promises and presents limitations. <i>FEMS Microbiology Reviews</i> , 2020, 44, 507-521.	3.9	65
33	Precursor peptide-targeted mining of more than one hundred thousand genomes expands the lanthipeptide natural product family. <i>BMC Genomics</i> , 2020, 21, 387.	1.2	102
34	The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis. <i>Seminars in Liver Disease</i> , 2020, 40, 298-306.	1.8	63
35	Faecal virome transplantation decreases symptoms of type 2 diabetes and obesity in a murine model. <i>Gut</i> , 2020, 69, 2122-2130.	6.1	142
36	Beneficial effects of LRP6-CRISPR on prevention of alcohol-related liver injury surpassed fecal microbiota transplant in a rat model. <i>Gut Microbes</i> , 2020, 11, 1015-1029.	4.3	29

#	ARTICLE	IF	CITATIONS
37	Microbiota in organ transplantation: An immunological and therapeutic conundrum?. Cellular Immunology, 2020, 351, 104080.	1.4	10
38	Immune-Microbiota Interplay and Colonization Resistance in Infection. Molecular Cell, 2020, 78, 597-613.	4.5	50
39	Seven facts and five initiatives for gut microbiome research. Protein and Cell, 2020, 11, 391-400.	4.8	21
40	Strategies to Facilitate Translational Advances from Microbiome Surveys. Trends in Microbiology, 2020, 28, 329-330.	3.5	7
41	Lessons Learned from Faecal Microbiota Transplantation in Cirrhosis. Current Hepatology Reports, 2020, 19, 159-167.	0.4	3
42	Molecular mechanisms of enterococcal-bacteriophage interactions and implications for human health. Current Opinion in Microbiology, 2020, 56, 38-44.	2.3	12
43	The intestinal microbiota and hepatocellular carcinoma. Memo - Magazine of European Medical Oncology, 2020, 13, 223-226.	0.3	4
44	Structural determinants of macrocyclization in substrate-controlled lanthipeptide biosynthetic pathways. Chemical Science, 2020, 11, 12854-12870.	3.7	25
45	Intestinal permeability, microbial translocation, changes in duodenal and fecal microbiota, and their associations with alcoholic liver disease progression in humans. Gut Microbes, 2020, 12, 1782157.	4.3	83
46	Deficiency of Intestinal Î±1â€²Fucosylation Exacerbates Ethanolâ€²Induced Liver Disease in Mice. Alcoholism: Clinical and Experimental Research, 2020, 44, 1842-1851.	1.4	11
47	Intestinal Virome in Patients With Alcoholic Hepatitis. Hepatology, 2020, 72, 2182-2196.	3.6	74
48	The Gut-liver Axis in Immune Remodeling: New insight into Liver Diseases. International Journal of Biological Sciences, 2020, 16, 2357-2366.	2.6	59
49	The Spatial Heterogeneity of the Gut Limits Predation and Fosters Coexistence of Bacteria and Bacteriophages. Cell Host and Microbe, 2020, 28, 390-401.e5.	5.1	122
50	Liver tissue microbiome in NAFLD: next step in understanding the gutâ€²liver axis?. Gut, 2020, 69, 1373-1374.	6.1	27
51	The role of infectious agents in cancer of the ocular region. Apmis, 2020, 128, 136-149.	0.9	2
52	Translating Pharmacomicrobiomics: Three Actionable Challenges/Prospects in 2020. OMICS A Journal of Integrative Biology, 2020, 24, 60-61.	1.0	5
53	Cytolysinâ€²positive <i>Enterococcus faecalis</i> is not increased in patients with nonâ€²alcoholic steatohepatitis. Liver International, 2020, 40, 860-865.	1.9	29
54	Bacteriophage Prevents Alcoholic Liver Disease. Cell, 2020, 180, 218-220.	13.5	12

#	ARTICLE	IF	CITATIONS
55	Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1003-1027.	1.8	123
57	Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia. <i>Translational Research</i> , 2020, 220, 167-181.	2.2	9
58	Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. <i>Journal of Gastroenterology</i> , 2020, 55, 588-614.	2.3	49
60	Substrate Recognition by the Class II Lanthipeptide Synthetase HalM2. <i>ACS Chemical Biology</i> , 2020, 15, 1473-1486.	1.6	24
61	Inflammation in Primary and Metastatic Liver Tumorigenesis—Under the Influence of Alcohol and High-Fat Diets. <i>Nutrients</i> , 2020, 12, 933.	1.7	15
62	The microbiome in inflammatory bowel diseases: from pathogenesis to therapy. <i>Protein and Cell</i> , 2021, 12, 331-345.	4.8	133
63	Microbial Products and Metabolites Contributing to Alcohol-Related Liver Disease. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2000023.	1.5	13
64	Between a Rock and a Soft Place: The Role of Viruses in Lithification of Modern Microbial Mats. <i>Trends in Microbiology</i> , 2021, 29, 204-213.	3.5	26
65	The gut mycobiome: a novel player in chronic liver diseases. <i>Journal of Gastroenterology</i> , 2021, 56, 1-11.	2.3	22
66	Targeting pathobionts for the treatment of alcohol-associated liver disease. <i>Liver International</i> , 2021, 41, 239-240.	1.9	1
67	Effect of silibinin on ethanol- or acetaldehyde-induced damage of mouse primary hepatocytes in vitro. <i>Toxicology in Vitro</i> , 2021, 70, 105047.	1.1	8
68	Interaction of bacterial metagenome and virome in patients with cirrhosis and hepatic encephalopathy. <i>Gut</i> , 2021, 70, 1162-1173.	6.1	53
69	Microbiota tryptophan metabolism induces aryl hydrocarbon receptor activation and improves alcohol-induced liver injury. <i>Gut</i> , 2021, 70, 1299-1308.	6.1	92
70	Impact of drinking alcohol on gut microbiota: recent perspectives on ethanol and alcoholic beverage. <i>Current Opinion in Food Science</i> , 2021, 37, 91-97.	4.1	32
71	Targeting the gut-liver-immune axis to treat cirrhosis. <i>Gut</i> , 2021, 70, 982-994.	6.1	88
72	Chronic Liver Diseases and the Microbiome—Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease. <i>Gastroenterology</i> , 2021, 160, 556-572.	0.6	49
73	Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 167-180.	8.2	97
74	Immunological mechanisms and therapeutic targets of fatty liver diseases. <i>Cellular and Molecular Immunology</i> , 2021, 18, 73-91.	4.8	98

#	ARTICLE	IF	CITATIONS
75	Phage Therapy for Alcohol-Associated Hepatitis. <i>Hepatology</i> , 2021, 73, 1609-1610.	3.6	3
76	Phages to shape the gut microbiota?. <i>Current Opinion in Biotechnology</i> , 2021, 68, 89-95.	3.3	34
77	Current Concepts, Opportunities, and Challenges of Gut Microbiome-Based Personalized Medicine in Nonalcoholic Fatty Liver Disease. <i>Cell Metabolism</i> , 2021, 33, 21-32.	7.2	98
78	Gut microbiome, liver immunology, and liver diseases. <i>Cellular and Molecular Immunology</i> , 2021, 18, 4-17.	4.8	182
79	A perspective of intestinal immune-microbiome interactions in alcohol-associated Liver Disease. <i>International Journal of Biological Sciences</i> , 2021, 17, 307-327.	2.6	15
80	Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma. <i>Cancer Discovery</i> , 2021, 11, 1248-1267.	7.7	117
81	Sustainable Microbiome: a symphony orchestrated by synthetic phages. <i>Microbial Biotechnology</i> , 2021, 14, 45-50.	2.0	6
82	Identification and characterization of two bacteriophages with lytic activity against multidrug-resistant <i>Escherichia coli</i> . <i>Virus Research</i> , 2021, 291, 198196.	1.1	6
83	New developments in RiPP discovery, enzymology and engineering. <i>Natural Product Reports</i> , 2021, 38, 130-239.	5.2	412
84	The potential missing links between hepatoprotective dioscin and alcoholic liver disease. <i>Liver International</i> , 2021, 41, 241-242.	1.9	3
85	Darwinian Medicine: We Evolved to Require Continuing Contact with the Microbiota of the Natural Environment. Evolution Turns the Inevitable into a Necessity. <i>Advances in Environmental Microbiology</i> , 2021, , 327-364.	0.1	3
86	Next-generation prebiotic promotes selective growth of bifidobacteria, suppressing <i>Clostridioides difficile</i> . <i>Gut Microbes</i> , 2021, 13, 1973835.	4.3	18
87	Mycobacteriophages as Potential Therapeutic Agents against Drug-Resistant Tuberculosis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 735.	1.8	20
88	The gut microbiota in hepatic encephalopathy. , 2021, , 187-204.		0
89	Associations of the gut microbiome with hepatic adiposity in the Multiethnic Cohort Adiposity Phenotype Study. <i>Gut Microbes</i> , 2021, 13, 1965463.	4.3	16
90	New Developments in Microbiome in Alcohol-Associated and Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , 2021, 41, 087-102.	1.8	10
92	Fecal transplantation alleviates acute liver injury in mice through regulating Treg/Th17 cytokines balance. <i>Scientific Reports</i> , 2021, 11, 1611.	1.6	30
93	No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics on Bacterial Translocation or Hepatic and Systemic Inflammation. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00306.	1.3	12

#	ARTICLE	IF	CITATIONS
94	Gut Microbiome and Liver Cancer. <i>Physiology in Health and Disease</i> , 2021, , 199-255.	0.2	0
95	Distinctive gut microbial dysbiosis between chronic alcoholic fatty liver disease and metabolic-associated fatty liver disease in mice. <i>Experimental and Therapeutic Medicine</i> , 2021, 21, 418.	0.8	19
96	Serum Acylcarnitines Associated with High Short-Term Mortality in Patients with Alcoholic Hepatitis. <i>Biomolecules</i> , 2021, 11, 281.	1.8	7
97	Alteration of Gut Microbiota in Carbapenem-Resistant Enterobacteriaceae Carriers during Fecal Microbiota Transplantation According to Decolonization Periods. <i>Microorganisms</i> , 2021, 9, 352.	1.6	11
98	Fungi-Bacteria Correlation in Alcoholic Hepatitis Patients. <i>Toxins</i> , 2021, 13, 143.	1.5	12
99	Phage-Bacteria Interactions in Potential Applications of Bacteriophage vB_EfaS-271 against <i>Enterococcus faecalis</i> . <i>Viruses</i> , 2021, 13, 318.	1.5	21
100	Systemic Immunoregulatory Consequences of Gut Commensal Translocation. <i>Trends in Immunology</i> , 2021, 42, 137-150.	2.9	26
101	Exploring Mucin as Adjunct to Phage Therapy. <i>Microorganisms</i> , 2021, 9, 509.	1.6	12
102	Novel treatments for alcoholic hepatitis. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 179-186.	1.0	6
104	Probing the "Dark Matter" of the Human Gut Phageome: Culture Assisted Metagenomics Enables Rapid Discovery and Host-Linking for Novel Bacteriophages. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 616918.	1.8	25
105	Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. <i>Seminars in Liver Disease</i> , 2021, 41, 191-205.	1.8	10
106	The Gut-Liver Axis in Cholestatic Liver Diseases. <i>Nutrients</i> , 2021, 13, 1018.	1.7	29
107	MetaPrism: A versatile toolkit for joint taxa/gene analysis of metagenomic sequencing data. <i>G3: Genes, Genomes, Genetics</i> , 2021, 11, .	0.8	1
108	Comparison of <i>Enterococcus faecalis</i> Biofilm Removal Efficiency among Bacteriophage PBEF129, Its Endolysin, and Cefotaxime. <i>Viruses</i> , 2021, 13, 426.	1.5	7
109	Deoxycholic Acid and Lithocholic Acid Alleviate Liver Injury and Inflammation in Mice with <i>Klebsiella pneumoniae</i> -Induced Liver Abscess and Bacteremia. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 777-789.	1.6	8
110	The relationship between the phageome and human health: are bacteriophages beneficial or harmful microbes?. <i>Beneficial Microbes</i> , 2021, 12, 107-120.	1.0	7
111	Dietary Modulation of Bacteriophages as an Additional Player in Inflammation and Cancer. <i>Cancers</i> , 2021, 13, 2036.	1.7	7
112	Gut dysbiosis as a driver in alcohol-induced liver injury. <i>JHEP Reports</i> , 2021, 3, 100220.	2.6	46

#	ARTICLE	IF	CITATIONS
113	Gut Microbiota and NAFLD: Pathogenetic Mechanisms, Microbiota Signatures, and Therapeutic Interventions. <i>Microorganisms</i> , 2021, 9, 957.	1.6	81
114	Alcohol-associated intestinal dysbiosis alters mucosal-associated invariant T cell phenotype and function. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 934-947.	1.4	9
115	Does over a century of aerobic phage work provide a solid framework for the study of phages in the gut?. <i>Anaerobe</i> , 2021, 68, 102319.	1.0	5
116	Comparative Analysis of the Microbiome across the Gut-Skin Axis in Atopic Dermatitis. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4228.	1.8	23
117	Lytic Bacteriophages Facilitate Antibiotic Sensitization of <i>Enterococcus faecium</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	1.4	30
118	Gut microbiota and non-alcoholic fatty liver disease. <i>Minerva Gastroenterology</i> , 2022, 67, .	0.3	10
119	A Healthy Gut for a Healthy Brain: Preclinical, Clinical and Regulatory Aspects. <i>Current Neuropharmacology</i> , 2021, 19, 610-628.	1.4	15
120	Altered Gut Microbial Metabolism of Essential Nutrients in Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2021, 160, 1784-1798.e0.	0.6	69
121	Malnutrition and Alcohol-Associated Hepatitis. <i>Clinics in Liver Disease</i> , 2021, 25, 557-570.	1.0	16
122	Rethinking phage-bacteria-eukaryotic relationships and their influence on human health. <i>Cell Host and Microbe</i> , 2021, 29, 681-688.	5.1	36
123	Human Gut Microbiome and Liver Diseases: From Correlation to Causation. <i>Microorganisms</i> , 2021, 9, 1017.	1.6	16
124	Phages and their lysins: Toolkits in the battle against foodborne pathogens in the postantibiotic era. <i>Comprehensive Reviews in Food Science and Food Safety</i> , 2021, 20, 3319-3343.	5.9	13
125	New technologies for developing phage-based tools to manipulate the human microbiome. <i>Trends in Microbiology</i> , 2022, 30, 131-142.	3.5	20
126	Current and Future Biomarkers in Alcoholic Hepatitis. <i>Clinics in Liver Disease</i> , 2021, 25, 493-516.	1.0	2
127	LanCLs add glutathione to dehydroamino acids generated at phosphorylated sites in the proteome. <i>Cell</i> , 2021, 184, 2680-2695.e26.	13.5	34
128	Profiling of tumour-associated microbiota in human hepatocellular carcinoma. <i>Scientific Reports</i> , 2021, 11, 10589.	1.6	47
129	The Role of the Microbiome in Liver Cancer. <i>Cancers</i> , 2021, 13, 2330.	1.7	16
131	The role of the gut microbiome and intestinal barrier in liver diseases. <i>Modern Gastroenterology</i> , 2021, , .	0.1	0

#	ARTICLE	IF	CITATIONS
132	The role of gut microbiota in tumorigenesis and treatment. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111444.	2.5	19
133	Obeticholic Acid Decreases Intestinal Content of <i>Enterococcus</i> in Rats With Cirrhosis and Ascites. <i>Hepatology Communications</i> , 2021, 5, 1507-1517.	2.0	4
134	Colesevelam Reduces Ethanol-Induced Liver Steatosis in Humanized Gnotobiotic Mice. <i>Cells</i> , 2021, 10, 1496.	1.8	6
135	Enterically derived high-density lipoprotein restrains liver injury through the portal vein. <i>Science</i> , 2021, 373, .	6.0	87
136	Structure-Activity Relationships of the Enterococcal Cytolysin. <i>ACS Infectious Diseases</i> , 2021, 7, 2445-2454.	1.8	7
137	Characterization of Anti-Bacterial Effect of the Two New Phages against Uropathogenic <i>Escherichia coli</i> . <i>Viruses</i> , 2021, 13, 1348.	1.5	5
138	The microbiota in cirrhosis and its role in hepatic decompensation. <i>Journal of Hepatology</i> , 2021, 75, S67-S81.	1.8	107
139	Intestinal hypoxia-inducible factor 2 β regulates lactate levels to shape the gut microbiome and alter thermogenesis. <i>Cell Metabolism</i> , 2021, 33, 1988-2003.e7.	7.2	80
140	Diagnosis and Treatment of Alcohol-Associated Liver Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 165.	3.8	144
141	Microbiome therapeutics for hepatic encephalopathy. <i>Journal of Hepatology</i> , 2021, 75, 1452-1464.	1.8	37
142	Ellagic Acid Prevents Binge Alcohol-Induced Leaky Gut and Liver Injury through Inhibiting Gut Dysbiosis and Oxidative Stress. <i>Antioxidants</i> , 2021, 10, 1386.	2.2	17
143	Intestinal virome and therapeutic potential of bacteriophages in liver disease. <i>Journal of Hepatology</i> , 2021, 75, 1465-1475.	1.8	28
144	Elevated Systemic and Intestinal Inflammatory Response Are Associated With Gut Microbiome Disorder After Cardiovascular Surgery. <i>Frontiers in Microbiology</i> , 2021, 12, 686648.	1.5	9
145	Complement System in Alcohol-Associated Liver Disease. <i>Immunology Letters</i> , 2021, 236, 37-50.	1.1	13
146	The Gut Microbiota-Derived Immune Response in Chronic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8309.	1.8	15
147	The promise of the gut microbiome as part of individualized treatment strategies. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 7-25.	8.2	60
148	Protective Property of Scutellarin Against Liver Injury Induced by Carbon Tetrachloride in Mice. <i>Frontiers in Pharmacology</i> , 2021, 12, 710692.	1.6	14
149	<i>Enterococcus</i> peptidoglycan remodeling promotes checkpoint inhibitor cancer immunotherapy. <i>Science</i> , 2021, 373, 1040-1046.	6.0	158

#	ARTICLE	IF	CITATIONS
151	Aryl Hydrocarbon Receptor Deficiency in Intestinal Epithelial Cells Aggravates Alcohol-Related Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 233-256.	2.3	26
152	Daily Dose of Bovine Lactoferrin Prevents Ethanol-Induced Liver Injury and Death in Male Mice by Regulating Hepatic Alcohol Metabolism and Modulating Gut Microbiota. <i>Molecular Nutrition and Food Research</i> , 2021, 65, e2100253.	1.5	17
153	Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis. <i>Gastroenterology</i> , 2021, 161, 508-521.e7.	0.6	33
154	Environmental exposure as a risk-modifying factor in liver diseases: Knowns and unknowns. <i>Acta Pharmaceutica Sinica B</i> , 2021, 11, 3768-3778.	5.7	6
155	Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. <i>FASEB Journal</i> , 2021, 35, e21871.	0.2	20
156	Molecular and Cellular Mediators of the Gut-Liver Axis in the Progression of Liver Diseases. <i>Frontiers in Medicine</i> , 2021, 8, 725390.	1.2	30
158	The human microbiome in transplantation: the past, present, and future. <i>Current Opinion in Organ Transplantation</i> , 2021, 26, 595-602.	0.8	2
159	Bacteriophage-mediated modulation of microbiota for diseases treatment. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113856.	6.6	18
160	Bacteriophage-Bacteria Interactions in the Gut: From Invertebrates to Mammals. <i>Annual Review of Virology</i> , 2021, 8, 95-113.	3.0	17
161	The Gut-Lung Axis in Cystic Fibrosis. <i>Journal of Bacteriology</i> , 2021, 203, e0031121.	1.0	44
162	Gut-Liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota. <i>Cancer Science</i> , 2021, 112, 4433-4443.	1.7	49
163	Gut microbiome in liver pathophysiology and cholestatic liver disease. <i>Liver Research</i> , 2021, 5, 151-163.	0.5	6
164	Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. <i>World Journal of Gastroenterology</i> , 2021, 27, 6161-6179.	1.4	12
165	Gut microbiota exaggerates triclosan-induced liver injury via gut-liver axis. <i>Journal of Hazardous Materials</i> , 2022, 421, 126707.	6.5	52
166	Alcoholic fatty liver disease inhibited the co-expression of Fmo5 and PPAR α to activate the NF- κ B signaling pathway, thereby reducing liver injury via inducing gut microbiota disturbance. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 18.	3.5	33
167	An enriched biosignature of gut microbiota-dependent metabolites characterizes maternal plasma in a mouse model of fetal alcohol spectrum disorder. <i>Scientific Reports</i> , 2021, 11, 248.	1.6	21
168	Changes of Gut-Microbiota-Liver Axis in Hepatitis C Virus Infection. <i>Biology</i> , 2021, 10, 55.	1.3	16
169	Host-microbiota interactions in immune-mediated diseases. <i>Nature Reviews Microbiology</i> , 2020, 18, 521-538.	13.6	254

#	ARTICLE	IF	CITATIONS
173	The gut microbiome: what every gastroenterologist needs to know. <i>Frontline Gastroenterology</i> , 2021, 12, 118-127.	0.9	16
174	Regulating Intestinal Microbiota in the Prevention and Treatment of Alcohol-Related Liver Disease. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2020, 2020, 1-10.	0.8	11
175	From intestinal dysbiosis to alcohol-associated liver disease. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 595-605.	4.5	24
176	Emerging medical therapies for severe alcoholic hepatitis. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 686-696.	4.5	17
177	Role of gut microbiota via the gut-liver-brain axis in digestive diseases. <i>World Journal of Gastroenterology</i> , 2020, 26, 6141-6162.	1.4	77
178	Gut microbiota mediated molecular events and therapy in liver diseases. <i>World Journal of Gastroenterology</i> , 2020, 26, 7603-7618.	1.4	20
179	Modulating the gut-liver axis and the pivotal role of the faecal microbiome in cirrhosis. <i>Clinical Medicine</i> , 2020, 20, 493-500.	0.8	6
180	Customized materials-assisted microorganisms in tumor therapeutics. <i>Chemical Society Reviews</i> , 2021, 50, 12576-12615.	18.7	43
181	Novel Virulent Bacteriophage Î SG005, Which Infects <i>Streptococcus gordonii</i> , Forms a Distinct Clade among <i>Streptococcus</i> Viruses. <i>Viruses</i> , 2021, 13, 1964.	1.5	4
182	<i>Auricularia auricula</i> Melanin Protects against Alcoholic Liver Injury and Modulates Intestinal Microbiota Composition in Mice Exposed to Alcohol Intake. <i>Foods</i> , 2021, 10, 2436.	1.9	14
183	Interplay of Gut Microbes and Aryl Hydrocarbon Receptor in Alcohol-Associated Liver Disease. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2022, 13, 343-345.	2.3	0
184	A Previously Undescribed Highly Prevalent Phage Identified in a Danish Enteric Virome Catalog. <i>MSystems</i> , 2021, 6, e0038221.	1.7	22
185	Lipoprotein Z, a hepatotoxic lipoprotein, predicts outcome in alcohol-associated hepatitis. <i>Hepatology</i> , 2022, 75, 968-982.	3.6	3
187	Phages fight alcoholic hepatitis. <i>Nature Reviews Drug Discovery</i> , 2020, 19, 20-20.	21.5	1
188	The Role of Gut Dysbiosis in Acute-on-Chronic Liver Failure. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11680.	1.8	7
189	The Effects of Moderate Alcohol Consumption on Circulating Metabolites and Gut Microbiota in Patients With Coronary Artery Disease. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 767692.	1.1	7
190	Progress and prospects of the healthy human gut virome. <i>Current Opinion in Virology</i> , 2021, 51, 164-171.	2.6	13
191	Therapeutic Perspectives and Mechanistic Insights of Phage Therapy in Allograft Transplantation. <i>Transplantation</i> , 2021, 105, 1449-1458.	0.5	13

#	ARTICLE	IF	CITATIONS
192	Gut non-bacterial microbiota contributing to alcohol-associated liver disease. <i>Gut Microbes</i> , 2021, 13, 1984122.	4.3	16
193	The Mucosally-Adherent Rectal Microbiota Contains Features Unique to Alcohol-Related Cirrhosis. <i>Gut Microbes</i> , 2021, 13, 1987781.	4.3	10
194	Bacteriophage Application and Biological Safety (or How Should I Train My Dog Not to Bite Me). , 2020, , 309-333.		0
195	Faecal microbiota transplantation: Application in treatment of some digestive diseases and safety concerns. <i>World Chinese Journal of Digestology</i> , 2020, 28, 135-143.	0.0	0
196	Multiple bacterial virulence factors focused on adherence and biofilm formation associate with outcomes in cirrhosis. <i>Gut Microbes</i> , 2021, 13, 1993584.	4.3	5
197	What is unknown in using microbiota as a therapeutic?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 39-44.	1.4	11
198	Role of the Gut Microbiota in Parenteral Nutritionâ€‘Associated Liver Disease: From Current Knowledge to Future Opportunities. <i>Journal of Nutrition</i> , 2022, 152, 377-385.	1.3	7
200	Current Management and Future Treatment of Alcoholic Hepatitis. <i>Gastroenterology and Hepatology</i> , 2020, 16, 178-189.	0.2	1
201	Update on the Role of the Gut Microbiota on Alcohol-Associated Liver Disease. <i>Gastroenterology and Hepatology</i> , 2021, 17, 381-383.	0.2	0
202	Interleukin-9 attenuates inflammatory response and hepatocyte apoptosis in alcoholic liver injury. <i>Life Sciences</i> , 2022, 288, 120180.	2.0	11
203	Dietary Patterns and Associated Microbiome Changes that Promote Oncogenesis. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 725821.	1.8	8
204	Bacteriophages and their potential for treatment of gastrointestinal diseases. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 135-144.	8.2	46
205	Gut microbiota and immune system in liver cancer: Promising therapeutic implication from development to treatment. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1616-1631.	0.8	5
206	Cross-Genus â€œBoot-Upâ€‘of Synthetic Bacteriophage in <i>Staphylococcus aureus</i> by Using a New and Efficient DNA Transformation Method. <i>Applied and Environmental Microbiology</i> , 2022, 88, AEM0148621.	1.4	6
207	Clinical characteristics and outcome of patients with enterococcal liver abscess. <i>Scientific Reports</i> , 2021, 11, 22265.	1.6	8
209	Carnosol inhibits the growth and biofilm of <i>Candida albicans</i> . <i>Journal De Mycologie Medicale</i> , 2022, 32, 101234.	0.7	5
210	Microbial Therapeutics in Liver Disease. , 2022, , 271-285.		1
211	Gut microbial trimethylamine is elevated in alcohol-associated hepatitis and contributes to ethanol-induced liver injury in mice. <i>ELife</i> , 2022, 11, .	2.8	21

#	ARTICLE	IF	CITATIONS
212	The role of gut microbiota in clinical complications, disease severity, and treatment response in severe alcoholic hepatitis. <i>Indian Journal of Gastroenterology</i> , 2022, 41, 37-51.	0.7	7
213	Major tail proteins of bacteriophages of the order Caudovirales. <i>Journal of Biological Chemistry</i> , 2022, 298, 101472.	1.6	37
214	Intake of <i>Bifidobacterium lactis</i> Probio-M8 fermented milk protects against alcoholic liver disease. <i>Journal of Dairy Science</i> , 2022, 105, 2908-2921.	1.4	11
215	Machine Learning Applied to Omics Datasets Predicts Mortality in Patients with Alcoholic Hepatitis. <i>Metabolites</i> , 2022, 12, 41.	1.3	6
217	Colesevelam ameliorates non-alcoholic steatohepatitis and obesity in mice. <i>Hepatology International</i> , 2022, 16, 359-370.	1.9	15
218	Gut Microbiome and Alcohol-associated Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1349-1359.	0.4	12
220	Severe alcoholic hepatitis as precipitant for organ failure and ACLF. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 67-76.	0.2	1
221	Liver specific, systemic and genetic contributors to alcohol-related liver disease progression. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 36-44.	0.2	2
222	The contribution of phage therapy to medical knowledge. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 28, 238-240.	0.9	6
223	Current Medical Treatment for Alcohol-Associated Liver Disease. <i>Journal of Clinical and Experimental Hepatology</i> , 2022, 12, 1333-1348.	0.4	15
224	Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. <i>Biomolecules</i> , 2022, 12, 56.	1.8	98
225	Blurring the line between opportunistic pathogens and commensals. , 2022, , 133-155.		0
226	Investigation and characterization of human gut phageome in advanced liver cirrhosis of defined etiologies. <i>Gut Pathogens</i> , 2022, 14, 9.	1.6	1
227	Bacteriophage protein Gp46 is a cross-species inhibitor of nucleoid-associated HU proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	7
228	Pyocyanin Modulates Gastrointestinal Transformation and Microbiota. <i>Journal of Agricultural and Food Chemistry</i> , 2022, 70, 2722-2732.	2.4	4
229	Synergistic and Detrimental Effects of Alcohol Intake on Progression of Liver Steatosis. <i>International Journal of Molecular Sciences</i> , 2022, 23, 2636.	1.8	11
230	Lantibiotic-encoding <i>Streptococcus</i> in the human microbiome are underlying risk factors for liver diseases. <i>Journal of Infection</i> , 2022, , .	1.7	2
231	Immune Response of an Oral <i>Enterococcus faecalis</i> Phage Cocktail in a Mouse Model of Ethanol-Induced Liver Disease. <i>Viruses</i> , 2022, 14, 490.	1.5	6

#	ARTICLE	IF	CITATIONS
232	Intestinal Microbiota Contributes to the Improvement of Alcoholic Hepatitis in Mice Treated With Schisandra chinensis Extract. <i>Frontiers in Nutrition</i> , 2022, 9, 822429.	1.6	6
233	Identification and Characterization of vB_PreP_EPr2, a Lytic Bacteriophage of Pan-Drug Resistant <i>Providencia rettgeri</i> . <i>Viruses</i> , 2022, 14, 708.	1.5	5
234	Conjugated linoleic acid ameliorates hepatic steatosis by modulating intestinal permeability and gut microbiota in ob/ob mice. <i>Food and Nutrition Research</i> , 2022, 66, .	1.2	17
235	The Role of Gut Bacteria and Fungi in Alcohol-Associated Liver Disease. <i>Frontiers in Medicine</i> , 2022, 9, 840752.	1.2	18
236	IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis. <i>Hepatology</i> , 2022, 76, 1058-1068.	3.6	41
237	<i>Enterococcus faecalis</i> Bacteriophage vB_EfaS_efap05-1 Targets the Surface Polysaccharide and ComEA Protein as the Receptors. <i>Frontiers in Microbiology</i> , 2022, 13, 866382.	1.5	1
238	Gut Microbiome Dysbiosis in Alcoholism: Consequences for Health and Recovery. <i>Frontiers in Cellular and Infection Microbiology</i> , 2022, 12, 840164.	1.8	19
239	Emerging enterococcus pore-forming toxins with MHC/HLA-I as receptors. <i>Cell</i> , 2022, 185, 1157-1171.e22.	13.5	22
240	The unforeseen intracellular lifestyle of <i>Enterococcus faecalis</i> in hepatocytes. <i>Gut Microbes</i> , 2022, 14, 2058851.	4.3	6
241	Intestinal virome in patients with alcohol use disorder and after abstinence. <i>Hepatology Communications</i> , 2022, 6, 2058-2069.	2.0	18
242	Rehabilitation of a misbehaving microbiome: phages for the remodeling of bacterial composition and function. <i>IScience</i> , 2022, 25, 104146.	1.9	7
243	Intestinal Barrier in Human Health and Disease. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12836.	1.2	129
244	New progress in research of intestinal microbiota in fatty liver disease. <i>World Chinese Journal of Digestology</i> , 2021, 29, 1355-1361.	0.0	0
245	Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 426.	1.8	37
246	RNA-sequencing identifies novel transcriptomic signatures in intestinal failure-associated liver disease. <i>Journal of Pediatric Surgery</i> , 2022, 57, 158-165.	0.8	6
247	Novel drug discovery strategies for the treatment of decompensated cirrhosis. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 273-282.	2.5	0
248	The immunotoxicity, but not anti-tumor efficacy, of anti-CD40 and anti-CD137 immunotherapies is dependent on the gut microbiota. <i>Cell Reports Medicine</i> , 2021, 2, 100464.	3.3	15
249	Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. <i>Biomedicines</i> , 2022, 10, 46.	1.4	10

#	ARTICLE	IF	CITATIONS
250	CRIg on liver macrophages clears pathobionts and protects against alcoholic liver disease. <i>Nature Communications</i> , 2021, 12, 7172.	5.8	22
251	An Elevated FIB-4 Score Is Associated with an Increased Incidence of Depression among Outpatients in Germany. <i>Journal of Clinical Medicine</i> , 2022, 11, 2214.	1.0	3
252	Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection. <i>Clinical and Molecular Hepatology</i> , 2023, 29, 1-15.	4.5	3
253	Hierarchy-Assembled Dual Probiotics System Ameliorates Cholestatic Drug-Induced Liver Injury via Gut-Liver Axis Modulation. <i>Advanced Science</i> , 2022, 9, e2200986.	5.6	19
254	Distinct responsiveness to rifaximin in patients with hepatic encephalopathy depends on functional gut microbial species. <i>Hepatology Communications</i> , 2022, 6, 2090-2104.	2.0	15
255	Editorial: The Microbiome in Hepatobiliary and Intestinal Disease. <i>Frontiers in Physiology</i> , 2022, 13, 893074.	1.3	6
260	Macrophages as key regulators of liver health and disease. <i>International Review of Cell and Molecular Biology</i> , 2022, , 143-212.	1.6	18
261	Hepatic Protein and Phosphoprotein Signatures of Alcohol-Associated Cirrhosis and Hepatitis. <i>American Journal of Pathology</i> , 2022, 192, 1066-1082.	1.9	8
262	Lipidomics for the Prediction of Progressive Liver Disease in Patients with Alcohol Use Disorder. <i>Metabolites</i> , 2022, 12, 433.	1.3	6
263	Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells. <i>Cancers</i> , 2022, 14, 2381.	1.7	4
264	Therapeutic Targeting of the Respiratory Microbiome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 535-544.	2.5	24
265	Identification of a protective <i>Bacteroides</i> strain of alcoholic liver disease and its synergistic effect with pectin. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 3735-3749.	1.7	5
266	Fermented milk of cheese-derived <i>Lactobacillus</i> subsp. <i>bulgaricus</i> displays potentials in alleviating alcohol-induced hepatic injury and gut dysbiosis in mice. <i>Food Research International</i> , 2022, 157, 111283.	2.9	6
267	Review article: current and emerging therapies for acute alcohol-associated hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 28-40.	1.9	11
268	Therapeutic advances in alcohol-associated hepatitis. <i>Journal of Hepatology</i> , 2022, 76, 1279-1290.	1.8	11
269	Promises of microbiome-based therapies. <i>Journal of Hepatology</i> , 2022, 76, 1379-1391.	1.8	33
270	Natural History of Alcohol-Associated Liver Disease: Understanding the Changing Landscape of Pathophysiology and Patient Care. <i>Gastroenterology</i> , 2022, 163, 840-851.	0.6	7
271	Local barriers configure systemic communications between the host and microbiota. <i>Science</i> , 2022, 376, 950-955.	6.0	20

#	ARTICLE	IF	CITATIONS
272	Harnessing stepping-stone hosts to engineer, select, and reboot synthetic bacteriophages in one pot. <i>Cell Reports Methods</i> , 2022, 2, 100217.	1.4	8
274	Microbiome as an immune regulator in health, disease, and therapeutics. <i>Advanced Drug Delivery Reviews</i> , 2022, 188, 114400.	6.6	11
275	The Beneficial Effects of Natural Extracts and Bioactive Compounds on the Gut-Liver Axis: A Promising Intervention for Alcoholic Liver Disease. <i>Antioxidants</i> , 2022, 11, 1211.	2.2	8
276	The role of virome in the gastrointestinal tract and beyond. <i>FEMS Microbiology Reviews</i> , 2022, 46, .	3.9	10
277	Metabolic-associated fatty liver disease from childhood to adulthood: State of art and future directions. <i>World Journal of Hepatology</i> , 2022, 14, 1087-1098.	0.8	1
278	Protective and aggressive bacterial subsets and metabolites modify hepatobiliary inflammation and fibrosis in a murine model of PSC. <i>Gut</i> , 2023, 72, 671-685.	6.1	30
279	Autism Spectrum Disorder and Fetal Alcohol Spectrum Disorder: A Literature Review. <i>Brain Sciences</i> , 2022, 12, 792.	1.1	12
280	Macrophage-derived MLKL in alcohol-associated liver disease: Regulation of phagocytosis. <i>Hepatology</i> , 2023, 77, 902-919.	3.6	15
281	Early Diagnosis and Prevention of Infections in Cirrhosis. <i>Seminars in Liver Disease</i> , 2022, 42, 293-312.	1.8	17
282	The gut virome: A new microbiome component in health and disease. <i>EBioMedicine</i> , 2022, 81, 104113.	2.7	93
283	Transcriptional and Epigenetic Regulation of Monocyte and Macrophage Dysfunction by Chronic Alcohol Consumption. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
284	Bacteriophage-Resistant Mutant of <i>Enterococcus faecalis</i> Is Impaired in Biofilm Formation. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	6
285	Targeted Antimicrobial Agents as Potential Tools for Modulating the Gut Microbiome. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	7
286	Preliminary Reproducibility Evaluation of a Phage Susceptibility Testing Method Using a Collection of <i>Escherichia coli</i> and <i>Staphylococcus aureus</i> Phages. <i>Journal of Applied Laboratory Medicine</i> , 2022, 7, 1468-1475.	0.6	4
287	Personalized therapy with bacteriophages of digestive diseases. <i>Jurnal Infektologii</i> , 2022, 14, 47-54.	0.1	0
288	Nanocapping-enabled charge reversal generates cell-enterable endosomal-escapable bacteriophages for intracellular pathogen inhibition. <i>Science Advances</i> , 2022, 8, .	4.7	14
289	Advances and challenges in cataloging the human gut virome. <i>Cell Host and Microbe</i> , 2022, 30, 908-916.	5.1	15
290	Role of gut bacterial and non-bacterial microbiota in alcohol-associated liver disease: Molecular mechanisms, biomarkers, and therapeutic prospective. <i>Life Sciences</i> , 2022, 305, 120760.	2.0	21

#	ARTICLE	IF	CITATIONS
291	Pre-treatment with phages achieved greater protection of mice against infection with Shiga toxin-producing <i>Escherichia coli</i> than post-treatment. <i>Research in Veterinary Science</i> , 2022, 150, 72-78.	0.9	3
292	Impact of a phage cocktail targeting <i>Escherichia coli</i> and <i>Enterococcus faecalis</i> as members of a gut bacterial consortium in vitro and in vivo. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	6
293	Gut microbiota contribution to hepatocellular carcinoma manifestation in non-alcoholic steatohepatitis. <i>World Journal of Hepatology</i> , 2022, 14, 1277-1290.	0.8	1
294	Elevation of enterococcus-specific antibodies associated with bacterial translocation is predictive of survival rate in chronic liver disease. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
295	New insights into the bile acid-based regulatory mechanisms and therapeutic perspectives in alcohol-related liver disease. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	2.4	5
296	Endoplasmic reticulum-targeted inhibition of CYP2E1 with vitamin E nanoemulsions alleviates hepatocyte oxidative stress and reverses alcoholic liver disease. <i>Biomaterials</i> , 2022, 288, 121720.	5.7	20
297	<i>Poria cocos</i> polysaccharide prevents alcohol-induced hepatic injury and inflammation by repressing oxidative stress and gut leakiness. <i>Frontiers in Nutrition</i> , 0, 9, .	1.6	12
298	Emerging Biomarkers in Alcohol-associated Hepatitis. <i>Journal of Clinical and Experimental Hepatology</i> , 2023, 13, 103-115.	0.4	1
299	Acetate reprograms gut microbiota during alcohol consumption. <i>Nature Communications</i> , 2022, 13, .	5.8	34
300	A seed-like hydrogel with metabolic cascade microbiota for oral treatment of liver failure. <i>Materials Today</i> , 2022, 58, 30-40.	8.3	5
301	Probiotic <i>Lactobacilli</i> ameliorate alcohol-induced hepatic damage via gut microbial alteration. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	7
302	Myths and Misconceptions around Antibiotic Resistance: Time to Get Rid of Them. <i>Infection and Chemotherapy</i> , 2022, 54, 393.	1.0	9
303	Effect of cofactors on NAFLD/NASH and MAFLD. A paradigm illustrating the pathomechanics of organ dysfunction. , 2022, 2, 12.		19
304	A review on the protective effect of active components in <i>Antrodia camphorata</i> against alcoholic liver injury. <i>Journal of Ethnopharmacology</i> , 2023, 300, 115740.	2.0	5
305	Intestinal homeostasis in autoimmune liver diseases. <i>Chinese Medical Journal</i> , 2022, 135, 1642-1652.	0.9	5
306	Intestinal phages interact with bacteria and are involved in human diseases. <i>Gut Microbes</i> , 2022, 14, .	4.3	26
307	Enteric VIP-producing neurons maintain gut microbiota homeostasis through regulating epithelium fucosylation. <i>Cell Host and Microbe</i> , 2022, 30, 1417-1434.e8.	5.1	16
308	Pathophysiological Prerequisites and Therapeutic Potential of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis. <i>Russian Archives of Internal Medicine</i> , 2022, 12, 352-362.	0.0	0

#	ARTICLE	IF	CITATIONS
309	Hawk Tea Flavonoids as Natural Hepatoprotective Agents Alleviate Acute Liver Damage by Reshaping the Intestinal Microbiota and Modulating the Nrf2 and NF- κ B Signaling Pathways. <i>Nutrients</i> , 2022, 14, 3662.	1.7	6
310	Jia-ga-song-tang protection against alcoholic liver and intestinal damage. <i>Frontiers in Pharmacology</i> , 0, 13, .	1.6	2
312	Bile Duct Colonization With <i>Enterococcus</i> sp. Associates With Disease Progression in Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1223-1232.e3.	2.4	13
313	A shared mucosal gut microbiota signature in primary sclerosing cholangitis before and after liver transplantation. <i>Hepatology</i> , 2023, 77, 715-728.	3.6	16
314	Mechanism of Action of Ribosomally Synthesized and Post-Translationally Modified Peptides. <i>Chemical Reviews</i> , 2022, 122, 14722-14814.	23.0	49
315	Gut metagenome-derived signature predicts hepatic decompensation and mortality in NAFLD-related cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 0, , .	1.9	3
316	Current Status of Phage Therapy against Infectious Diseases and Potential Application beyond Infectious Diseases. <i>International Journal of Clinical Practice</i> , 2022, 2022, 1-22.	0.8	7
317	Targeting the Gut Microbiome in Cirrhosis. , 2022, , 311-319.		1
318	Recent Findings in the Gut-Liver Axis and Associated Disease Therapy. <i>European Medical Journal Hepatology</i> , 0, , 4-16.	1.0	0
319	Topic: Nutrition and the Gut-Liver-Brain Axis. <i>Current Hepatology Reports</i> , 2022, 21, 99-110.	0.4	1
320	Role of Intestinal Microbes in Chronic Liver Diseases. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12661.	1.8	12
321	Herbal formula BaWeiBaiDuSan alleviates polymicrobial sepsis-induced liver injury via increasing the gut microbiota <i>Lactobacillus johnsonii</i> and regulating macrophage anti-inflammatory activity in mice. <i>Acta Pharmaceutica Sinica B</i> , 2023, 13, 1164-1179.	5.7	12
322	Current Research on the Pathogenesis of NAFLD/NASH and the Gut-Liver Axis: Gut Microbiota, Dysbiosis, and Leaky-Gut Syndrome. <i>International Journal of Molecular Sciences</i> , 2022, 23, 11689.	1.8	21
323	Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2023, 18, 411-438.	9.6	25
324	Gut microbiome and neurosurgery: Implications for treatment. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	3
325	Editing of a Specific Strain of <i>Escherichia coli</i> in the Mouse Gut Using Native Phages. <i>Microbiology Spectrum</i> , 0, , .	1.2	0
327	Gut-liver axis: Pathophysiological concepts and clinical implications. <i>Cell Metabolism</i> , 2022, 34, 1700-1718.	7.2	118
328	Isolation and characterization of novel <i>Fusobacterium nucleatum</i> bacteriophages. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	5

#	ARTICLE	IF	CITATIONS
329	Microbiome and Human Health: Current Understanding, Engineering, and Enabling Technologies. <i>Chemical Reviews</i> , 2023, 123, 31-72.	23.0	54
330	The microbiota and the gut-liver axis in primary sclerosing cholangitis. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 135-154.	8.2	22
331	Gut dysbiosis in nonalcoholic fatty liver disease: pathogenesis, diagnosis, and therapeutic implications. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	32
332	Correlation between Serum Steroid Hormones and Gut Microbiota in Patients with Alcohol-Associated Liver Disease. <i>Metabolites</i> , 2022, 12, 1107.	1.3	1
333	Longitudinal transkingdom gut microbial approach towards decompensation in outpatients with cirrhosis. <i>Gut</i> , 2023, 72, 759-771.	6.1	2
334	Viral metagenomics combined with metabolomics reveals the role of gut viruses in mouse model of depression. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
335	Dose-effect of polystyrene microplastics on digestive toxicity in chickens (<i>Gallus gallus</i>): Multi-omics reveals critical role of gut-liver axis. <i>Journal of Advanced Research</i> , 2023, 52, 3-18.	4.4	16
336	Encapsulation and delivery of phage as a novel method for gut flora manipulation in situ: A review. <i>Journal of Controlled Release</i> , 2023, 353, 634-649.	4.8	13
337	35kDa hyaluronan ameliorates ethanol driven loss of anti-microbial defense and intestinal barrier integrity in a TLR4-dependent manner. <i>Matrix Biology</i> , 2023, 115, 71-80.	1.5	1
338	Evolving concepts of host-pathobiont interactions in autoimmunity. <i>Current Opinion in Immunology</i> , 2023, 80, 102265.	2.4	6
339	Commensal cow <i>Roseburia</i> reduces gut-dysbiosis-induced mastitis through inhibiting bacterial translocation by producing butyrate in mice. <i>Cell Reports</i> , 2022, 41, 111681.	2.9	24
340	Design of a Bacteriophage Cocktail Active against <i>Shigella</i> Species and Testing of Its Therapeutic Potential in <i>Galleria mellonella</i> . <i>Antibiotics</i> , 2022, 11, 1659.	1.5	2
341	Engineered Phage with Aggregation-Induced Emission Photosensitizer in Cocktail Therapy against Sepsis. <i>Advanced Materials</i> , 2023, 35, .	11.1	13
342	The central role of the gut in intensive care. <i>Critical Care</i> , 2022, 26, .	2.5	13
343	Effects of dietary irritants on intestinal homeostasis and the intervention strategies. <i>Food Chemistry</i> , 2023, 409, 135280.	4.2	4
344	The gut microbiome: a core regulator of metabolism. <i>Journal of Endocrinology</i> , 2023, 256, .	1.2	18
345	Fecal Microbiota Transplantation and Other Gut Microbiota Manipulation Strategies. <i>Microorganisms</i> , 2022, 10, 2424.	1.6	13
346	Advancing alcohol-related liver disease: from novel biomarkers to refining selection for liver transplantation. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 71-72.	8.2	4

#	ARTICLE	IF	CITATIONS
347	Catecholamine induces Kupffer cell apoptosis via growth differentiation factor 15 in alcohol-associated liver disease. <i>Experimental and Molecular Medicine</i> , 2023, 55, 158-170.	3.2	4
348	Phage therapy: From biological mechanisms to future directions. <i>Cell</i> , 2023, 186, 17-31.	13.5	125
349	The mechanism of thia-Michael addition catalyzed by LanC enzymes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2023, 120, .	3.3	6
350	Microbiota and Liver Cancer. , 2023, , 67-90.		1
351	Pathophysiological changes of the liver-muscle axis in end-stage liver disease: what is the right target?. <i>Acta Gastro-Enterologica Belgica</i> , 2022, 85, 611-624.	0.4	12
352	Alcohol-Associated Hepatitis. <i>New England Journal of Medicine</i> , 2022, 387, 2436-2448.	13.9	58
354	Can a mucosal microbiota signature predict disease severity, survival, and disease recurrence in PSC?. <i>Hepatology</i> , 2023, 77, 709-711.	3.6	1
355	Microbial derived antimicrobial peptides as potential therapeutics in atopic dermatitis. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
356	Recent progress in gut microbiota. , 2023, 1, 27-31.		2
357	Primer set for detecting enterococcal bacteriophages. , 2023, 2, 91-97.		0
358	Hepatic pIgR-mediated secretion of IgA limits bacterial translocation and prevents ethanol-induced liver disease in mice. <i>Gut</i> , 2023, 72, 1959-1970.	6.1	8
359	<i>Malassezia restricta</i> promotes alcohol-induced liver injury. <i>Hepatology Communications</i> , 2023, 7, e0029-e0029.	2.0	5
360	Rheumatic diseases: The microbiota-immunity axis in development and treatment. , 2023, , 83-111.		0
361	Differences in Bacterial Translocation and Liver Injury in Ethanol Versus Diet-Induced Liver Disease. <i>Digestive Diseases and Sciences</i> , 2023, 68, 3059-3069.	1.1	9
362	Microbiota-directed biotherapeutics: considerations for quality and functional assessment. <i>Gut Microbes</i> , 2023, 15, .	4.3	5
363	Research Priorities for Precision Medicine in NAFLD. <i>Clinics in Liver Disease</i> , 2023, 27, 535-551.	1.0	6
364	Gut microbiota axis: potential target of phytochemicals from plant-based foods. <i>Food Science and Human Wellness</i> , 2023, 12, 1409-1426.	2.2	5
365	A Taxonomy-Agnostic Approach to Targeted Microbiome Therapeuticsâ€”Leveraging Principles of Systems Biology. <i>Pathogens</i> , 2023, 12, 238.	1.2	1

#	ARTICLE	IF	CITATIONS
367	Modulating phenylalanine metabolism by <i>L. acidophilus</i> alleviates alcohol-related liver disease through enhancing intestinal barrier function. <i>Cell and Bioscience</i> , 2023, 13, .	2.1	13
368	Alcohol, Inflammation, and Microbiota in Alcoholic Liver Disease. <i>International Journal of Molecular Sciences</i> , 2023, 24, 3735.	1.8	16
370	A High-Salt Diet Exacerbates Liver Fibrosis through <i>Enterococcus</i> -Dependent Macrophage Activation. <i>Microbiology Spectrum</i> , 2023, 11, .	1.2	4
372	Anti-miR-96 and Hh pathway inhibitor MDB5 synergistically ameliorate alcohol-associated liver injury in mice. <i>Biomaterials</i> , 2023, 295, 122049.	5.7	3
373	Potential therapies for acute-chronic liver failure. <i>Liver International</i> , 0, , .	1.9	6
374	Gut microbiome-based strategies for host health and disease. <i>Critical Reviews in Food Science and Nutrition</i> , 0, , 1-16.	5.4	2
375	IgY antibodies against cytolysin reduce ethanol-induced liver disease in mice. <i>Hepatology</i> , 2023, 78, 295-306.	3.6	4
377	Microbiota-related metabolites fueling the understanding of ischemic heart disease. , 2023, 2, .		3
378	Alcohol-Associated Liver Disease: Integrated Management With Alcohol Use Disorder. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 2124-2134.	2.4	6
379	Synthesis of Fluorescent Lanthipeptide Cytolysin S Analogues by Late-Stage Sulfamidate Ring Opening. <i>Organic Letters</i> , 2023, 25, 1431-1435.	2.4	1
380	Rifaximin for liver fibrosis in patients with alcohol-related liver disease (GALA-RIF): a randomised, double-blind, placebo-controlled, phase 2 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2023, 8, 523-532.	3.7	21
381	Impact Assessment of vB_KpnP_K1-ULIP33 Bacteriophage on the Human Gut Microbiota Using a Dynamic In Vitro Model. <i>Viruses</i> , 2023, 15, 719.	1.5	4
382	Current and emerging therapies for alcohol-associated hepatitis. <i>Liver Research</i> , 2023, 7, 35-46.	0.5	2
383	Emerging targets for therapy in ALD: lessons from NASH. <i>Hepatology</i> , 0, Publish Ahead of Print, .	3.6	1
384	Fatty Liver Disease. , 2024, , 330-401.		1
385	Large-scale phage cultivation for commensal human gut bacteria. <i>Cell Host and Microbe</i> , 2023, 31, 665-677.e7.	5.1	10
386	Gut Microbiota Modulation: A Viable Strategy to Address Medical Needs in Hepatocellular Carcinoma and Liver Transplantation. <i>Engineering</i> , 2023, 29, 59-72.	3.2	8
387	The role of the gut microbiome in the development of hepatobiliary cancers. <i>Hepatology</i> , 0, , .	3.6	4

#	ARTICLE	IF	CITATIONS
388	Targeting the human gut microbiome with small-molecule inhibitors. <i>Nature Reviews Chemistry</i> , 2023, 7, 319-339.	13.8	4
389	Gut-liver axis: barriers and functional circuits. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2023, 20, 447-461.	8.2	26
391	Phage therapy in gut microbiome. <i>Progress in Molecular Biology and Translational Science</i> , 2023, , .	0.9	0
398	The modulatory approaches of microbiome therapeutics. , 2023, , 95-126.		0
406	Immune response to intestinal microbial dysbiosis. , 2023, , 125-136.		0
408	Drinking and laboratory biomarkers, and nutritional status characterize the clinical presentation of early-stage alcohol-associated liver disease. <i>Advances in Clinical Chemistry</i> , 2023, , 83-108.	1.8	1
440	Extracellular Vesicles and Fatty Liver. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 129-141.	0.8	1
448	Mechanisms of Recovery from and Strategies for Survival of Severe Alcoholic Hepatitis and ACLF. , 2023, , 1245-1263.		0
454	Gut Microbiome and Liver Diseases from the Perspective of 3PM: The Predictive, Preventive, and Personalized Medicine. <i>Advances in Predictive, Preventive and Personalised Medicine</i> , 2023, , 141-175.	0.6	0
461	Gut liver brain axis in diseases: the implications for therapeutic interventions. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	3
464	Utilization of the microbiome in personalized medicine. <i>Nature Reviews Microbiology</i> , 0, , .	13.6	5
474	Gut Microbiome and Hepatic Steatosis (Steatotic Liver Disease). <i>Endocrinology</i> , 2024, , 1-21.	0.1	0
481	Gut Microbiome and Hepatic Steatosis (Steatotic Liver Disease). <i>Endocrinology</i> , 2024, , 177-197.	0.1	0